We're applying our scientific expertise and proprietary technology to create and deliver next generation RNA therapeutics.
Our preclinical drug development pipeline is initially focused in three key therapeutic areas with high potential to deliver meaningful patient results.
Oncology
We are developing immuno-oncology treatments and vaccines to uniquely stimulate a patient's immune system for the specific destruction of cancer cells present in the body.
Genetic Disorders
We are developing therapeutics to address genetic disorders.
Infectious Disease
We are advancing next generation RNA vaccines to help provide significant protection against common infectious diseases currently plaguing millions of people around the globe.